anti-CD155 monoclonal antibody

An anti-CD155 monoclonal antibody is a therapeutic antibody designed to target the poliovirus receptor (PVR, also known as CD155), an emerging immune checkpoint ligand overexpressed on various solid tumors. CD155 interacts with several receptors on T cells and natural killer (NK) cells, including the inhibitory receptors TIGIT and CD96, and the costimulatory receptor CD226 (DNAM-1). By binding to CD155, these antibodies block its immunosuppressive interactions with TIGIT and CD96, while also preventing the internalization and degradation of CD226, thereby restoring CD226 surface expression and enhancing anti-tumor immune responses. Clinical-stage candidates in this class, such as Nectin Therapeutics' NTX1088 and TG ImmunoPharma's TGI-5, are currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, both as monotherapies and in combination with other immune checkpoint inhibitors like pembrolizumab.

Other names

CD155 antibodyCD-155 antibodyCD 155 antibodyCD155 monoclonal antibodyCD-155 monoclonal antibodyCD 155 monoclonal antibodyPVR antibodyPVR monoclonal antibodyanti-CD155 antibodyanti-CD-155 antibodyanti-CD 155 antibodyanti-PVR antibodyanti-PVR monoclonal antibody